Nical trials performed in OS patients with recurrence, chemoresistance, or lung metastasis identified moderately clinical responses in subgroup of individuals.28,29 Ideally, experimental investigation of expression of tyrosine kinases may be the prerequisite for picking sufferers who will obtain a accurate benefit from this targeted remedy. Certainly one of these trials examined the expression and